CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain ...
Phase 3
Budapest, Hungary and 108 other locations
VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation...
Phase 3
Budapest, Hungary and 261 other locations
venetoclax in participants with treatment-naïve AML. Phase 2 Combination Therapy is an open-label, single arm, study evaluating the efficac...
Phase 2, Phase 3
Budapest, Hungary and 71 other locations
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible f...
Phase 3
Budapest, Hungary and 172 other locations
combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute...
Phase 3
Budapest, Hungary and 285 other locations
available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second ...
Phase 3
Budapest, Hungary and 73 other locations
Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and a risk of death ...
Phase 3
Székesfehérvár, Fejér, Hungary and 223 other locations
This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a...
Phase 4
Budapest, Hungary and 96 other locations
Clinical trials
Research sites
Resources
Legal